AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18502689 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative video
Number of subjects: 93
Study 18502689 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 93
Study 17448045 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed brackets (S)
Number of subjects: 16
Study 17448045 — intervention group
Group type: EXPERIMENTAL
Intervention: GAC brackets (G)
Number of subjects: 16
Study 17448045 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 16
Study 14752639 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (ABP)
Number of subjects: 974
Study 14752639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 974
Study 12002922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg IV
Number of subjects: 45
Study 12002922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg IV
Number of subjects: 45
Study 12002922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9653594 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride plus insulin (GI)
Number of subjects: 145
Study 9653594 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus insulin (PI)
Number of subjects: 145
Study 8582105 — intervention group
Group type: COMPARATOR
Intervention: Low level counselling (one practice appointment and five telephone counselling appointments)
Number of subjects: 0
Study 8582105 — intervention group
Group type: COMPARATOR
Intervention: High level counselling (six appointments in general practice)
Number of subjects: 0
Study 2708607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 77
Study 2708607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment combined with response prevention of vomiting
Number of subjects: 77
Study 2708607 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 77
Study 797215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 16
Study 797215 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 16
Study 31038717 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb exercise
Number of subjects: 75
Study 31038717 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Number of subjects: 75
Study 31038717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 29057266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered double-lead threads single implants placed at the time of tooth extraction (TG)
Number of subjects: 92
Study 29057266 — intervention group
Group type: COMPARATOR
Intervention: Tapered double-lead threads single implants placed 3 months after extraction (CG)
Number of subjects: 92
Study 25597411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle change plus dental care (LCDC) program
Number of subjects: 132
Study 25597411 — intervention group
Group type: COMPARATOR
Intervention: Routine program (control)
Number of subjects: 132
Study 23378222 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sexual visual cues ON dopamine medication
Number of subjects: 12
Study 23378222 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sexual visual cues OFF dopamine medication
Number of subjects: 12
Study 23378222 — intervention group
Group type: COMPARATOR
Intervention: Control group (Parkinson's disease patients without hypersexuality)
Number of subjects: 12
Study 20033250 — intervention group
Group type: EXPERIMENTAL
Intervention: Introductory exemplary questions before completing the SF-36 questionnaire
Number of subjects: 215
Study 20033250 — intervention group
Group type: COMPARATOR
Intervention: Standardized SF-36 imputation algorithm
Number of subjects: 215
Study 19477891 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg daily for 14 days)
Number of subjects: 4372
Study 19477891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372
Study 19477891 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 4372
Study 17761995 — intervention group
Group type: EXPERIMENTAL
Intervention: Invited for screening for type 2 diabetes
Number of subjects: 7380
Study 17761995 — intervention group
Group type: COMPARATOR
Intervention: Not invited (controls)
Number of subjects: 7380
Study 15188323 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (lecture, audit, reminder mailing)
Number of subjects: 373
Study 15188323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special education)
Number of subjects: 373
Study 11440560 — intervention group
Group type: COMPARATOR
Intervention: Placebo antitussive syrup (60 ml)
Number of subjects: 22
Study 11440560 — intervention group
Group type: COMPARATOR
Intervention: Untreated state
Number of subjects: 22
Study 11440560 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 22
Study 9130756 — intervention group
Group type: EXPERIMENTAL
Intervention: PN group (embryos cryopreserved at the pronucleate stage)
Number of subjects: 364
Study 9130756 — intervention group
Group type: COMPARATOR
Intervention: EC group (embryos frozen at the 2- to 4-cell stage)
Number of subjects: 364
Study 9130756 — intervention group
Group type: EXPERIMENTAL
Intervention: PN group (thawed embryos)
Number of subjects: 364
Study 9130756 — intervention group
Group type: COMPARATOR
Intervention: EC group (thawed embryos)
Number of subjects: 364
Study 9130756 — intervention group
Group type: EXPERIMENTAL
Intervention: PN group
Number of subjects: 364
Study 9130756 — intervention group
Group type: COMPARATOR
Intervention: EC group
Number of subjects: 364
Study 1958435 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-68,798 (5 micrograms kg-1)
Number of subjects: 12
Study 1958435 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-68,798 (10 micrograms kg-1)
Number of subjects: 12
Study 1958435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6129752 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-receptor blockers (talinolol and propranolol)
Number of subjects: 118
Study 31928846 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (56 subjects) with cognitive and structural variables compared between converters and nonconverters.
Number of subjects: 113
Study 31928846 — intervention group
Group type: COMPARATOR
Intervention: Group B (57 subjects) with cognitive and structural variables compared to Group A.
Number of subjects: 113
Study 31474148 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapatellar approach
Number of subjects: 95
Study 31474148 — intervention group
Group type: COMPARATOR
Intervention: Infrapatellar approach
Number of subjects: 95
Study 29044556 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-based intervention
Number of subjects: 26
Study 26027450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance training
Number of subjects: 54
Study 24548129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone (50 mg/day)
Number of subjects: 60
Study 24548129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23217477 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia (1.5 ml of 0.75% hyperbaric bupivacaine)
Number of subjects: 60
Study 23217477 — intervention group
Group type: COMPARATOR
Intervention: Bilateral spinal anaesthesia (1.5 ml of 0.75% hyperbaric bupivacaine)
Number of subjects: 60
Study 20382445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.15 μg/kg sufentanil, followed by 0.075 μg/kg every 3 minutes
Number of subjects: 108
Study 20382445 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 0.15 mg/kg morphine, followed by 0.075 mg/kg
Number of subjects: 108
Study 20382445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups experienced adverse events
Number of subjects: 108
Study 18650074 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet transform‐complex‐valued artificial neural network (WT‐CVANN)
Number of subjects: 78
Study 18650074 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex wavelet transform‐complex‐valued artificial neural network (CWT‐CVANN)
Number of subjects: 78
Study 18650074 — intervention group
Group type: COMPARATOR
Intervention: Real-valued artificial neural network (RVANN)
Number of subjects: 78
Study 15997043 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary specialized outpatient clinic care
Number of subjects: 230
Study 15997043 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 230
Study 12709777 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg LY354740
Number of subjects: 44
Study 12709777 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg LY354740
Number of subjects: 44
Study 12709777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10498345 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/day of nasal spray of salmon calcitonin
Number of subjects: 34
Study 10498345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8732311 — intervention group
Group type: EXPERIMENTAL
Intervention: triprolidine-D
Number of subjects: 12
Study 8732311 — intervention group
Group type: EXPERIMENTAL
Intervention: astemizole-D
Number of subjects: 12
Study 8732311 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 1403034 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 250 mg four times per day and hydrocortisone 20 mg twice per day
Number of subjects: 354
Study 1403034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 4002791 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg muzolimine after a standardized breakfast with 1760 mg aluminium hydroxide administered 10 min before breakfast
Number of subjects: 6
Study 4002791 — intervention group
Group type: COMPARATOR
Intervention: 40 mg muzolimine after a standardized breakfast without aluminium hydroxide
Number of subjects: 6
Study 30681351 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 8
Study 30681351 — intervention group
Group type: COMPARATOR
Intervention: 21% O2 (room air)
Number of subjects: 8
Study 29882333 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27852385 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinghuaweikang capsules + furazolidone-based triple therapy (group A1)
Number of subjects: 357
Study 27852385 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinghuaweikang capsules + furazolidone-based quadruple therapy (group A2)
Number of subjects: 357
Study 27852385 — intervention group
Group type: COMPARATOR
Intervention: Bismuth potassium citrate + furazolidone-based triple therapy (group B1)
Number of subjects: 357
Study 27852385 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate + furazolidone-based quadruple therapy (group B2)
Number of subjects: 357
Study 25134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter tourniquet around both uterine vessels (Group 1)
Number of subjects: 67
Study 25134294 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet (Control Group 2)
Number of subjects: 67
Study 23173249 — intervention group
Group type: EXPERIMENTAL
Intervention: qi supplementing, collateral dredging, detoxifying, and turbidity descending recipe (QSCDDTDR) combined with basic methods of Western medicine (WM)
Number of subjects: 160
Study 23173249 — intervention group
Group type: COMPARATOR
Intervention: niaoduqing granule (NDQG)
Number of subjects: 160
Study 20351374 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied at LU6, LI4, ST36 and ST6 for 30 min after exercise
Number of subjects: 12
Study 20351374 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (rest without acupuncture)
Number of subjects: 12
Study 18056557 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Youth in the Caribbean (FOYC) plus Caribbean Informed Parents and Children Together (CImPACT)
Number of subjects: 1282
Study 18056557 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Youth in the Caribbean (FOYC) plus an attention control for parents (Goal for It [GFI])
Number of subjects: 1282
Study 18056557 — intervention group
Group type: COMPARATOR
Intervention: Wonderous Wetlands (WW) plus the GFI
Number of subjects: 1282
Study 18056557 — intervention group
Group type: EXPERIMENTAL
Intervention: CImPACT (for parents)
Number of subjects: 1282
Study 16043810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) with varying duty-cycles
Number of subjects: 0
Study 16043810 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard duty-cycles of VNS
Number of subjects: 0
Study 12170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (pronase, sodium bicarbonate, and DMPS plus water)
Number of subjects: 160
Study 12170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (pronase only with water)
Number of subjects: 160
Study 12170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (pronase and sodium bicarbonate plus water)
Number of subjects: 160
Study 12170403 — intervention group
Group type: COMPARATOR
Intervention: Group A (DMPS alone)
Number of subjects: 160
Study 12170403 — intervention group
Group type: COMPARATOR
Intervention: Group B (DMPS plus water)
Number of subjects: 160
Study 12170403 — intervention group
Group type: EXPERIMENTAL
Intervention: CLO test results
Number of subjects: 160
Study 10444932 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance angiography (CE MRA)
Number of subjects: 23
Study 10444932 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 23
Study 7480918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levamisole
Number of subjects: 20
Study 7480918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of alive BCG plus autoclaved M. leprae
Number of subjects: 20
Study 7480918 — intervention group
Group type: COMPARATOR
Intervention: Mitsuda antigen retesting
Number of subjects: 20
Study 2340610 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg.kg‐1), fentanyl (1 microgram.kg‐1), propofol (2 mg.kg‐1), succinylcholine (1 mg.kg‐1), anaesthesia maintained with propofol (6 mg.kg‐1.hr‐1), N2O (67 per cent), O2 (33 per cent)
Number of subjects: 19
Study 2340610 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (4 mg.kg‐1), anaesthesia maintained with N2O (67 per cent), O2 (33 per cent), enflurane (0.5 per cent inspired concentration)
Number of subjects: 19
Study 6767648 — intervention group
Group type: EXPERIMENTAL
Intervention: Butalamine hydrochloride (Adrevil forte) 3 x 2 tablets daily
Number of subjects: 32
Study 6767648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6767648 — intervention group
Group type: EXPERIMENTAL
Intervention: Butalamine hydrochloride (Adrevil forte)
Number of subjects: 32
Study 31498394 — intervention group
Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 60
Study 31498394 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 60
Study 31425552 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 1000
Study 31425552 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 1000
Study 31425552 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics (age and gender)
Number of subjects: 1000
Study 31425552 — intervention group
Group type: EXPERIMENTAL
Intervention: History of dispensing
Number of subjects: 1000
Study 27878873 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval training for hyperphagia behavior (6-week duration)
Number of subjects: 97
Study 27878873 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 97
Study 27878873 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval training
Number of subjects: 97
Study 24956415 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet for 8 weeks
Number of subjects: 48
Study 24956415 — intervention group
Group type: COMPARATOR
Intervention: Control diet for 8 weeks
Number of subjects: 48
Study 23422925 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg daily for 13 days
Number of subjects: 18
Study 23422925 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg daily for 13 days in MDR1 3435 TT individuals
Number of subjects: 18
Study 23422925 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg daily for 13 days in MDR1 3435 CT individuals
Number of subjects: 18
Study 22027785 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/day
Number of subjects: 60
Study 22027785 — intervention group
Group type: COMPARATOR
Intervention: Benazepril 10 mg/day
Number of subjects: 60
Study 19427431 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 6632
Study 19427431 — intervention group
Group type: COMPARATOR
Intervention: No history of hypertension
Number of subjects: 6632
Study 19427431 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension (in patients without previous HF)
Number of subjects: 6632
Study 19427431 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension (in patients with previous HF)
Number of subjects: 6632
Study 17978327 — intervention group
Group type: EXPERIMENTAL
Intervention: Training staff in community mental health teams to deliver substance misuse interventions
Number of subjects: 13
Study 15308911 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous morphine infusion (20 mg/day)
Number of subjects: 50
Study 15308911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no morphine)
Number of subjects: 50
Study 11554438 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg)
Number of subjects: 6
Study 11554438 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (375 mg)
Number of subjects: 6
Study 11554438 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (500 mg)
Number of subjects: 6
Study 11554438 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (all doses)
Number of subjects: 6
Study 9755997 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (PPI) administered through a jejunal tube after PPPD
Number of subjects: 42
Study 9755997 — intervention group
Group type: COMPARATOR
Intervention: Saline solution administered through a jejunal tube (Control group)
Number of subjects: 42
Study 8148274 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% w/v erythromycin with 1.2% w/v zinc acetate
Number of subjects: 0
Study 8148274 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% w/v erythromycin alone
Number of subjects: 0
Study 8148274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both erythromycin with and without zinc
Number of subjects: 0
Study 3280316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 5 mg kg‐1 with Tween 80 (A)
Number of subjects: 20
Study 3280316 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amiodarone 5 mg kg‐1 without Tween 80 (N)
Number of subjects: 20
Study 29797913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medication (dehydration and nutritional nerve treatment), treatment given once daily for 6 times per course, with 4 courses total.
Number of subjects: 64
Study 29797913 — intervention group
Group type: COMPARATOR
Intervention: Western medication (dehydration and nutritional nerve treatment) alone.
Number of subjects: 64
Study 28169487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 50
Study 28169487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26062002 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18(2D)
Number of subjects: 1075
Study 22917636 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2 (bisacodyl the day before and 2-L polyethylene glycol with citrates and simethicone on the day of colonoscopy)
Number of subjects: 153
Study 22917636 — intervention group
Group type: COMPARATOR
Intervention: Control group (split-dose of 4-L polyethylene glycol)
Number of subjects: 153
Study 22917636 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 1 (bisacodyl and 2-L polyethylene glycol with citrates and simethicone the day before)
Number of subjects: 153
Study 20697940 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianhuang Granule (THG)
Number of subjects: 60
Study 18403671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg of salbutamol aerosol with a spacer device for bronchodilation
Number of subjects: 628
Study 15684169 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg, 3 times a day for 10 days
Number of subjects: 69
Study 15684169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15684169 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 69
Study 12604505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion (60 micromol x kg(‐1) x min(‐1))
Number of subjects: 7
Study 12604505 — intervention group
Group type: COMPARATOR
Intervention: Isomolar sodium bicarbonate infusion
Number of subjects: 7
Study 10535525 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO) infusion
Number of subjects: 40
Study 10535525 — intervention group
Group type: COMPARATOR
Intervention: No DFO infusion
Number of subjects: 40
Study 10535525 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with beta-thalassemia major
Number of subjects: 40
Study 8724510 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicide as a Backup
Number of subjects: 199
Study 8724510 — intervention group
Group type: COMPARATOR
Intervention: Condoms Only
Number of subjects: 199
Study 8724510 — intervention group
Group type: COMPARATOR
Intervention: Condom and Spermicide
Number of subjects: 199
Study 8724510 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 199
Study 1768540 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral bupivacaine (PVB) infusion
Number of subjects: 20
Study 1768540 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral saline (PVS) infusion
Number of subjects: 20
Study 462160 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum intrapleurally as adjuvant therapy
Number of subjects: 475
Study 462160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475